Objectives of the Conference: 1. To exchange ideas and accomplishments related to: A. Clinical cancer chemoprevention studies. B. Development and standardization of surrogate endpoint biomarkers (SEB) of use in clinical trials of chemopreventive agents, including the use of computer-assisted image analysis (CIA), to increase the precision and quality assurance of SEB. C. Development of chemopreventive agents, including procurement in kilogram quantities, preclinical testing for efficacy and toxicity, and Phase I testing. 2. To explore the potential for collaborative clinical studies involving short-term Phase II trials using SEB, involving ambulatory subjects seen at a central hospital in Beijing. Overall Plan of the Conference. Approximately 15 participants from each country will attend. Each country will be responsible for providing travel funds and per diem costs to its participants. The U.S. will provide for the housing of all participants at the Holiday Inn Crowne Plaza and for costs associated with auditorium and audiovisual facilities. Participants will pay for their own meals, reception charges, and banquets.
| Schildkraut, J M; Halabi, S; Bastos, E et al. (2000) Prognostic factors in early-onset epithelial ovarian cancer: a population-based study. Obstet Gynecol 95:119-27 |
| Berchuck, A; Carney, M; Lancaster, J M et al. (1998) Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2. Clin Obstet Gynecol 41:157-66 |
| Schildkraut, J M; Bastos, E; Berchuck, A (1997) Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 89:932-8 |
| Elbendary, A A; Cirisano, F D; Evans Jr, A C et al. (1996) Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 2:1571-5 |
